Blog > US Stocks and Markets > Profit from the Biotech Boom
 | Email This Article Email This Article  | 

Profit from the Biotech Boom

Posted August 7, 2008

“Biotechs offer investors with opportunities to get in on breakthrough technologies, while they are still in the lab… So why have investors stopped investing in these ground-floor companies?” — Jim Nelson

Blogger’s note: Pharmaceutical companies are a well-known haven during a recession. The logic being that, while people may cut back on a lot, they’ll always buy their medications. But Big Pharma is currently bracing itself for a string of losses as its most profitable medications come out of their exclusive patents and face competition from generic drugs. So where can you find that recession safe haven now? In the same companies that Big Pharma is pursuing for the next generation of new medications:  Small biotech. But don’t take my word for it, read on below to learn more about the potential for profits in the U.S. biotech industry.

by Jim Nelson

Baltimore — (TFN):  Forget financial, energy, and retail companies. Well, maybe you shouldn’t just forget them. There are deals there, too. But, something much better is starting and you need to know about it…

For the past few years, Wall Street has beaten down one of the most lucrative industries in the whole lot of them… biotechs.

Biotechs offer investors with opportunities to get in on breakthrough technologies, while they are still in the lab. Many times, they also offer average people with a way to invest in future cures and solutions to the world’s most dangerous diseases. That’s quite a one-two punch.

So why have investors stopped investing in these ground-floor companies? Read on to learn the answer.

****Make sure you sign up for our FREE TFN News Feed for breaking news, special reports and new financial videos. You can pick your favorite reader. Or if you prefer, you can have the feed delivered to your email.

Related Articles


Posted by TFN-US · Filed Under US Stocks and Markets 

Comments

close Reblog this comment
Powered by Disqus · Learn more
blog comments powered by Disqus